Back

Plasma E-selectin and C-C motif chemokine ligand 3 differentiate pulmonary arterial hypertension from other forms of pulmonary hypertension and healthy controls

30 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Decoding heart failure: novel biomarkers and artificial intelligence Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Salaheldin Ahmed

Hospital of Helsingborg, Helsingborg (Sweden)

4 More presentations in this session

Presentation thumbnail
Machine learning phenotyping of HefpEF :a systematic review and meta analysis of validation cohorts with external generalizability assessment
Doctor J. Gohri (New Delhi, IN)
Abstract
Presentation thumbnail
Soluble transferrin receptor and hepcidin but not standard iron biomarkers are reliable prognostic biomarkers in heart failure
Doctor L. Lanser (Innsbruck, AT)
Abstract
Presentation thumbnail
BNP trajectory and the risk of heart failure hospitalisation in stage 2 CKM syndrome
Doctor K. Teramoto (Osaka, JP)
Abstract
Presentation thumbnail
Development of an enzyme-linked immunosorbent assay for versikine detection and first analyses in human cardiovascular disease
Mr S. Andrup (Oslo, NO)
Abstract

Access the full session

Session thumbnail
Decoding heart failure: novel biomarkers and artificial intelligence

The Event

Event poster

ESC Congress 2026

30 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Serum proteome profiling reflects the risk of pulmonary hypertension in chronic heart failure patients
1 July 2021
thumbnail
Webinar
What's new in pulmonary hypertension: diagnosis and phenotyping? ESC 2022 Clinical Practice Guidelines webinar
3 October 2022
thumbnail
Congress Presentation
Inhibin Beta-A is a novel gene involved in the development of pulmonary arterial hypertension through inhibiting BMPRII-signaling in endothelial cells
3 September 2019
thumbnail
Congress Presentation
Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources